Register by March 13th and SAVE $300*!
(Mention Promo Code: JZT974)
RegisterRequest BrochureView Website
Conference Chairman: Tony Dutta, Senior Vice President of Operations, IDISElite Speakers Include: Zareen Ahmed, Corporate Regulatory Affairs-Regulatory CMC, sanofi-aventis David Bernstein, Ph.D., Consultant, Bernstein CMC Regulatory Consulting Christina Butta, Senior Principal Scientist, Pfizer Inc Tiffany Cavallaro, Clinical Supply Planning Manager, Merck Scott Eaton, Regulatory CMC, Pfizer Inc Jim Krupa, Associate Director, Planning and Coordination, Cephalon Micheline Marshall, Director, Clinical Pharmacy, Wyeth Gail Owens, Corporate Regulatory Affairs-RCMC, sanofi-aventis Frank Reale, Associate Director, Worldwide Regulatory Coordination and Clinical Supplies, Merck John Simmons, CMC Consultant; Former Director, Office of New Drug Quality Assessment, FDA Mark Ware, Director, Clinical Trial Services, IDIS Jill Wechsler, Washington Editor, Pharmaceutical Executive Yolanda Bell, Global NAMP Business Process Owner, Amgen Chris Wilson, Chief Operating Officer, Keats Healthcare Ltd
www.cbinet.com/comparator
The First and Only Source for Invaluable Information on:
Market Dynamics Driving an Increase in Comparator Studies and Keys to Success
Selection:Register by 3/13/09 Standard
2-Day Conference $1695$1995
Conference Co-Sponsor:
http://www.idispharma.com/
2009 Sponsors:
http://www.myoderm.com/, http://www.myoderm.com/, http://www.almacgroup.com/pharmaservices/, http://www.adiramedica.com/, http://www.pharmarama.com/about.htm, http://www.bilcare.com/, http://www.keatshealthcare.co.uk/, http://www.multipharma.ch/
Offer not valid on workshop only or academic registrations.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.